Literature DB >> 32248060

Risk factors for depression in patients with epilepsy: A meta-analysis.

Yanhong Yang1, Mengyang Yang2, Qianling Shi3, Tiancheng Wang4, Min Jiang5.   

Abstract

BACKGROUND: Depression is common and associated with reduced quality of life (QoL) in people with epilepsy (PWE). Although multiple studies have investigated the relevant predictors, the results have been inconsistent. This meta-analysis aimed to investigate the risk factors that might increase the possibility of depression in this population.
METHODS: Medline, The Cochrane Library, Web of Science, and Embase were comprehensively searched for cross-sectional studies on the occurrence of depression in PWE. A random effects model was used to calculate the pooled hazard ratios (HRs) and 95% confidence intervals (95% CIs). Heterogeneity between the study results and the probability of publication bias were also assessed.
RESULTS: Fifty-one cross-sectional studies with sample sizes ranging from 36 to 1763 were included in this meta-analysis. The significant factors associated with an increased risk of depression were older age (odds ratio [OR]: 1.02, 95% CI: 1.00-1.04; p = 0.019), female gender (OR: 1.58, 95% CI: 1.30-1.93; p < 0.001), low education level (OR: 3.38, 95% CI: 2.86-4.00; p < 0.001), not being employed (OR: 1.61, 95% CI: 1.08-2.38; p = 0.019), poor antiepileptic drug (AED) adherence (OR: 2.84, 95% CI: 1.94-4.16; p < 0.001), polytherapy (OR: 2.25, 95% CI: 1.48-3.41; p < 0.001), stigma (OR: 2.22, 95% CI: 1.71-2.88; p < 0.001), and anxiety (OR: 2.21, 95% CI: 1.66-2.94; p < 0.001). A shorter epilepsy duration was significantly associated with a lower risk of depression (OR: 0.99, 95% CI: 0.99-0.99; p < 0.001), whereas marital status (OR: 1.07, 95% CI: 0.90-1.20; p = 0.684), economic level (OR: 1.01, 95% CI: 0.95-1.08; p = 0.684), age at seizure onset (OR: 0.99, 95% CI: 0.75-1.29; p = 0.912), and seizure control (OR: 1.03, 95% CI: 0.65-1.63; p = 0.900) did not increase the risk of depression.
CONCLUSION: This meta-analysis defined several factors related to an increased risk of depression in PWE and can contribute to better prevention and screening strategies for depression in this group. The mechanisms behind this comorbidity remain to be further investigated to determine individually appropriate and targeted interventions.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Depression; Epilepsy; Meta-analysis; Risk factor

Mesh:

Substances:

Year:  2020        PMID: 32248060     DOI: 10.1016/j.yebeh.2020.107030

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  6 in total

1.  Medium-term effects of COVID-19 pandemic on epilepsy: A follow-up study.

Authors:  Sofía Lallana; Elena Fonseca; Juan Luis Restrepo; Manuel Quintana; Iván Seijo-Raposo; Laura Abraira; Estevo Santamarina; José Álvarez-Sabín; Manuel Toledo
Journal:  Acta Neurol Scand       Date:  2021-04-27       Impact factor: 3.209

Review 2.  Depression and Anxiety in the Epilepsies: from Bench to Bedside.

Authors:  Vaishnav Krishnan
Journal:  Curr Neurol Neurosci Rep       Date:  2020-07-14       Impact factor: 6.030

3.  Depression in patients with epilepsy: screening, diagnosis and management.

Authors:  Amina Chentouf
Journal:  Tunis Med       Date:  2021 Mai

4.  Potential Pleiotropic Genes and Shared Biological Pathways in Epilepsy and Depression Based on GWAS Summary Statistics.

Authors:  Han Lin; Wan-Hui Lin; Feng Lin; Chang-Yun Liu; Chun-Hui Che; Hua-Pin Huang
Journal:  Comput Intell Neurosci       Date:  2022-04-12

5.  Depression and sexual functions in epilepsy patients: Comparison before and during the COVID-19 pandemic.

Authors:  Zeynep Bastug Gul
Journal:  Ann Med Psychol (Paris)       Date:  2021-02-16       Impact factor: 0.380

6.  Depressive symptoms in patients with epilepsy and clinically associated features in a single tertiary center.

Authors:  Mariacarolina Vacca; Mariana Fernandes; Matteo Spanetta; Fabio Placidi; Francesca Izzi; Caterina Lombardo; Nicola Biagio Mercuri; Claudio Liguori
Journal:  Neurol Sci       Date:  2021-09-15       Impact factor: 3.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.